ArticleScientific reports2026
Pacemaker implantation is associated with post-ablation atrial fibrillation recurrence mediated by plasma CILP1.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Atrial fibrillation (AF) recurrence following radiofrequency ablation (RFA) remains a significant clinical challenge, and pacemaker implantation may influence outcomes. However, the underlying molecular mechanisms are not well understood. This study aimed to investigate whether pacemaker implantation is statistically associated with of AF recurrence and to identify proteomic biomarkers associated with this statistical relationship. We conducted a propensity score-matched cohort study and performed Cox proportional hazards analysis to assess the association between pacemaker implantation and AF recurrence. Exploratory plasma proteomic profiling was performed to identify differentially expressed proteins (DEPs) in a pilot cohort of paroxysmal AF patients with and without pacemakers. An independent validation cohort was used to confirm the findings via Cox analysis and biomarker quantification, followed by statistical mediation analysis. In the discovery cohort, pacemaker implantation was identified as an independent risk factor for post-ablation AF recurrence (adjusted hazard ratio: 2.349, 95% CI: 1.065–5.179, p = 0.034). Exploratory proteomic analysis revealed significantly elevated levels of cartilage intermediate layer protein 1 (CILP1) in pacemaker patients. In the validation cohort, pacemaker implantation remained an independent predictor of AF recurrence, and plasma CILP1 levels were significantly statistically associated with recurrence risk (AUC: 0.737, 95% CI: 0.633–0.842, p = 0.0005). Statistical mediation analysis indicated that elevated CILP1 levels were indirectly associated with the relationship between pacemaker implantation and AF recurrence (p = 0.022). Pacemaker implantation is associated with an increased risk of AF recurrence following RFA. This risk appears to be partially statistically mediated by elevated plasma CILP1 levels. These findings suggest CILP1 may serve as a potential biomarker for AF risk stratification. Given the pilot nature of the proteomic screening, further large-scale studies are warranted to validate these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.